GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Treace Medical Concepts Inc (NAS:TMCI) » Definitions » Altman Z2-Score

Treace Medical Concepts (Treace Medical Concepts) Altman Z2-Score : 1.51 (As of Jun. 10, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Treace Medical Concepts Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Treace Medical Concepts has a Altman Z2-Score of 1.51, indicating it is in Grey Zones. This implies that Treace Medical Concepts is in some kind of financial stress. If it is below 1.1, the company may face bankrupcy risk.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Treace Medical Concepts's Altman Z2-Score or its related term are showing as below:

TMCI' s Altman Z2-Score Range Over the Past 10 Years
Min: 1.51   Med: 2.89   Max: 8.03
Current: 1.51

During the past 5 years, Treace Medical Concepts's highest Altman Z2-Score was 8.03. The lowest was 1.51. And the median was 2.89.


Treace Medical Concepts Altman Z2-Score Historical Data

The historical data trend for Treace Medical Concepts's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Treace Medical Concepts Altman Z2-Score Chart

Treace Medical Concepts Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z2-Score
- 2.91 5.87 1.54 2.34

Treace Medical Concepts Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.64 3.55 2.69 2.34 1.51

Competitive Comparison of Treace Medical Concepts's Altman Z2-Score

For the Medical Devices subindustry, Treace Medical Concepts's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Treace Medical Concepts's Altman Z2-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Treace Medical Concepts's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Treace Medical Concepts's Altman Z2-Score falls into.



Treace Medical Concepts Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Treace Medical Concepts's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.5782+3.26*-0.63+6.72*-0.2041+1.05*1.0864
=1.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2024:
Total Assets was $242.7 Mil.
Total Current Assets was $187.4 Mil.
Total Current Liabilities was $47.0 Mil.
Retained Earnings was $-152.9 Mil.
Pre-Tax Income was -18.676 + -6.281 + -17.521 + -12.271 = $-54.7 Mil.
Interest Expense was -1.317 + -1.304 + -1.296 + -1.282 = $-5.2 Mil.
Total Liabilities was $116.3 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(187.397 - 47.049)/242.726
=0.5782

X2=Retained Earnings/Total Assets
=-152.923/242.726
=-0.63

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-54.749 - -5.199)/242.726
=-0.2041

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(126.391 - 0)/116.335
=1.0864

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Treace Medical Concepts has a Altman Z2-Score of 1.51 indicating it is in Grey Zones.


Treace Medical Concepts  (NAS:TMCI) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Treace Medical Concepts Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of Treace Medical Concepts's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Treace Medical Concepts (Treace Medical Concepts) Business Description

Traded in Other Exchanges
N/A
Address
100 Palmetto Park Place, Ponte Vedra, FL, USA, 32081
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals.
Executives
F Barry Bays director
Betsy Hanna director C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE RD #150, PONTE VEDRA BEACH FL 32081
Deepti Jain director 3701 WAYZATA BLVD, MINNEAPOLIS MN 55416
Sean F. Scanlan officer: See Remarks C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
James T Treace director 117 BRISTOL PLACE, PONTE VEDRA BEACH FL 32082
Richard W Mott director 1221 CROSSMAN AVENUE, SUNNYVALE CA 94089
Thomas E Timbie director
Daniel E. Owens officer: Chief HR Officer C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
Scot Michael Elder officer: *See "Remarks" C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
Mark Hair officer: Chief Financial Officer C/O RESTORATION ROBOTICS, INC., 128 BAYTECH DRIVE, SAN JOSE CA 95134
Aaron Berutti officer: Sr. VP, Sales C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
John T. Treace director, 10 percent owner, officer: Chief Executive Officer C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
Lance A Berry director 5677 AIRLINE ROAD, ARLINGTON TN 38002
Jane E Kiernan director 525 W ROSCOE, CHICAGO IL 60657
John R Treace director 5677 AIRLINE RD, ARLINGTON VA 38002

Treace Medical Concepts (Treace Medical Concepts) Headlines

From GuruFocus

Treace to Report First Quarter 2023 Financial Results on May 8, 2023

By sperokesalga sperokesalga 04-20-2023

Treace Medical Concepts, Inc. Announces Proposed Public Offering of Common Stock

By Stock market mentor Stock market mentor 02-07-2023